Crossmark

Myositis and myocarditis with tremelimumab and durvalumab combination therapy for hepatocellular carcinoma

Crossref DOI link: https://doi.org/10.1016/j.medcli.2023.11.003

Published Print: 2024-04

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Lizondo López, Thais

Carro Méndez, Iria

Carcelero San Martín, Esther
License Information

Text and Data Mining valid from 2024-04-01
More Information

This article is maintained by: Elsevier

Article Title: Myositis and myocarditis with tremelimumab and durvalumab combination therapy for hepatocellular carcinoma

Journal Title: Medicina Clínica

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.medcli.2023.11.003

Content Type: simple-article

Copyright: © 2023 Elsevier España, S.L.U. All rights reserved.